Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Pacira BioSciences, Inc. before investing.

In this article, we go over a few key elements for understanding Pacira BioSciences, Inc.’s stock price such as:

• Pacira BioSciences, Inc.’s current stock price and volume
• Why Pacira BioSciences, Inc.’s stock price changed recently
• Upgrades and downgrades for PCRX from analysts
• PCRX’s stock price momentum as measured by its relative strength

About Pacira BioSciences, Inc. (PCRX)

Before we jump into Pacira BioSciences, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.

Want to learn more about Pacira BioSciences, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Pacira BioSciences, Inc..

Pacira BioSciences, Inc.’s Stock Price as of Market Close

As of March 13, 2026, 1:19 PM, CST, Pacira BioSciences, Inc.’s stock price was $23.370.

Pacira BioSciences, Inc. is down 0.68% from its previous closing price of $23.530.

During the last market session, Pacira BioSciences, Inc.’s stock traded between $23.035 and $23.650. Currently, there are approximately 42.49 million shares outstanding for Pacira BioSciences, Inc..

Pacira BioSciences, Inc.’s price-earnings (P/E) ratio is currently at 148.9, which is high compared to the Pharmaceuticals industry median of 19.4. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Pacira BioSciences, Inc. Stock Price History

Pacira BioSciences, Inc.’s (PCRX) price is currently up 6.66% so far this month.

During the month of March, Pacira BioSciences, Inc.’s stock price has reached a high of $23.910 and a low of $20.985.

Over the last year, Pacira BioSciences, Inc. has hit prices as high as $27.640 and as low as $18.800. Year to date, Pacira BioSciences, Inc.’s stock is down 9.7%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Pacira BioSciences, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of March 12, 2026, there were 0 analysts who downgraded Pacira BioSciences, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Pacira BioSciences, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Pacira BioSciences, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Pacira BioSciences, Inc.’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Pacira BioSciences, Inc. (PCRX) by visiting AAII Stock Evaluator.

Relative Price Strength of Pacira BioSciences, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of March 12, 2026, Pacira BioSciences, Inc. has a weighted four-quarter relative price strength of -2.74%, which translates to a Momentum Score of 42 and is considered to be Average.

Want to learn more about how Pacira BioSciences, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Pacira BioSciences, Inc. Stock Price: Bottom Line

As of March 13, 2026, Pacira BioSciences, Inc.’s stock price is $23.370, which is down 0.68% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Pacira BioSciences, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.